ArticleEClinicalMedicine2021
Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers.
Article in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.The journal of headache and pain · 2022Pooled it
- Evaluation of the safety profile of COVID-19 vaccines: a rapid review.BMC medicine · 2021Pooled it
- Short-term safety and reactogenicity of same-day COVID-19 and influenza vaccination in very old, community-dwelling adults.European geriatric medicine · 2026Observational
- Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions.Human vaccines & immunotherapeutics · 2025Article
- A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study.Human vaccines & immunotherapeutics · 2024Article
- Factors behind Antibiotic Therapy: A Survey of Primary Care Pediatricians in Lombardy.International journal of environmental research and public health · 2024Article
- Vaccination Open Day: A Cross-Sectional Study on the 2023 Experience in Lombardy Region, Italy.International journal of environmental research and public health · 2024Article
- The Effectiveness of the Third Dose of COVID-19 Vaccine: When Should It Be Performed?Vaccines · 2024Article
- COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities.Journal of medical ethics · 2024Article
- Article
- Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study).Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Article
- Response to the letter to the Editor regarding the article "Vaccine versus infection - COVID-19-related loss of training time in elite athletes".Journal of science and medicine in sport · 2023Article
- Vaccination, time lost from work, and COVID-19 infections: a Canadian healthcare worker retrospective cohort study.Frontiers in public health · 2023Article
- Side effects of COVID-19 vaccines in the middle eastern population.Frontiers in immunology · 2023Review
- The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study.Human vaccines & immunotherapeutics · 2022Observational
- Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan.Clinical drug investigation · 2022Observational
- Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine.Vaccines · 2022Article
- Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective Analysis.Vaccines · 2022Article
- Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.Vaccine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth care workers (HCWs) are at high risk of contracting an infection by SARS CoV-2 and thus they are a priority for vaccination. We hereby aim to investigate whether the risk of severe and moderate systemic symptoms (MSS) after vaccination is higher in HCWs with a history of previous COVID-19.
methodsAn online questionnaire was offered to the cohort all HCWs undergoing anti-SARS CoV-2 mRNA BNT162b2 vaccination between January 4th and February 9th 2021 in two large tertiary hospitals (ASST Santi Paolo and Carlo) in Milan, Italy. Previous SARS-CoV-2 infection/COVID-19 was recorded. Local and systemic symptoms after each of the two doses were reported. MSS were those either interfering with daily activities or resulting in time off-work. Factors associated to MSS were identified by logistic regression.
findings3,078 HCW were included. Previous SARS-CoV-2 infection/COVID-19 occurred in 396 subjects (12·9%). 59·6% suffered from
interpretationOur data confirm in a real-world setting, the lack of severe adverse events and the short duration of reactogenicity in already infected HCWs. Possible differences in immune reactivity are drivers of MSS among this group of HCWs, as well as among females and younger individuals.
fundingNone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.